Eravacycline combo for resistant pneumonia
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether adding eravacycline to standard treatment can help clear a tough lung infection caused by bacteria that don't respond to many antibiotics. It's for adults with pneumonia who have already started eravacycline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have pneumonia with symptoms and imaging that confirm it.
- You must have a lab test showing a carbapenem-resistant Acinetobacter baumannii infection from two sputum samples, with at least one from a deep lung sample.
- You must have already been treated with eravacycline for at least 3 days.
- You must be willing to sign a consent form (or have a legal guardian sign for you).
- You cannot have a serious allergy to tetracyclines or any ingredient in the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This study looks at how the drug eravacycline works in the body of critically ill patients whose first antibiotic didn't work. It aims to find the best dose to fight the infection.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial compares different treatment options for patients in the ICU who have a resistant bacterial infection called Acinetobacter baumannii. If you have this infection after surgery, the study aims to find the best way to treat it.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.